全球水产养殖疫苗市场——增长、趋势、COVID-19 影响和预测 (2023-2028)

在预测期内，全球水产养殖疫苗市场预计将以 6.2% 的复合年增长率增长。

COVID-19 大流行对动物产业产生了巨大影响。 由于封锁，动物饲料和其他食品以及基本动物药品的物流和供应链受到了重大影响，影响了所研究的市场。

根据 2021 年 9 月发布的海洋政策研究报告，COVID-19 大流行将导致运输成本增加（比正常情况高出约 20-60%），市场 COVID-19 对水产养殖疫苗市场产生了重大影响. 此外，第二波和第三波COVID-19感染在各国连续发生，预计短期内市场将不景气。 然而，随着限制措施的放鬆，市场有望在预测期内逐渐好转并恢復到大流行前的增长水平。

水生动物消费量的增加正在推动水产养殖业的增长，水产养殖疫苗预计将成为市场的主要增长动力，因为它们可以减少感染机会并提高产品产量，预测期预计将推动日本水产养殖疫苗市场的增长。

例如，根据联合国粮农组织（FAO）2022年的报告，全球水生动物产量约为1.78亿吨，占总产量的63%（1.12亿吨）。）在海洋中收穫（70% 来自圈养渔业，30% 来自水产养殖），37%（6600 万吨）在内陆水域收穫（83% 来自水产养殖，17% 来自圈养渔业）。 此外，根据同一份文件，全球海产品消费量正在增加，预计这将进一步推动水产养殖产量的增长。 消费量从 1961 年的 9 公斤增加到近几十年来的 20.2 公斤，影响人均海产品消费量的最大因素是供应增加、消费者偏好改变、技术发展和收入增加。 因此，新兴市场水产养殖业有望推动对更高产量的水产养殖疫苗的需求，预计将在预测期内推动水产养殖疫苗市场的增长。

预计会对水产养殖疫苗市场的增长产生重大影响的其他因素包括传染病在水生动物中的流行以及寻求抗击这些疾病的市场参与者。 例如，2022 年 2 月 Frontiers 发表的一项研究发现，异尖线虫在中国各地的鱼类中呈地方性流行，汇总发病率为 45.5%，其中鲜鱼发病率最高（58.1%）。 东海鱼类异尖线虫患病率最高（76.8%），中国东部地区患病率最高（55.3%）。 因此，由于该疾病的高流行率，预计对水产养殖疫苗的需求将增加，从而推动市场走向增长

此外，新的养殖疫苗进入市场有望进一步推动市场增长

例如，2021 年 4 月，印度农业研究委员会 - 苦咸水水产养殖中央研究所 (ICAR-CIBA) 报告说，许多海水、咸水和淡水鱼受到影响，幼虫期和早期幼虫期最多。重组疫苗 CIBA-Nodavac-R，针对病毒性神经坏死 (VNN)，其死亡率为 100%。 同样，2021 年 10 月，孟加拉国锡尔赫特农业大学 (SAU) 的一位教授开发了一种鱼类口服疫苗，可以保护不同种类的鱼类免受细菌性疾病的侵害并提高其产量。 该疫苗可混入鱼饲料后使用。

因此，由于上述因素，水产养殖疫苗市场有望在预测期内实现增长

但是，在未来五年内，对疫苗的严格监管可能会减缓所研究市场的增长。

水产养殖疫苗的市场趋势

在预测期内，活疫苗类型预计将占水产疫苗市场的很大份额

活疫苗包含仍然可以在宿主（接受者）体内繁殖的活的减毒微生物

该生物体已“减毒”，这意味着它已失去大部分致病能力，但仍保留一定程度的免疫原性。 活疫苗比灭活疫苗更具免疫原性，并以类似于自然感染的方式激发各种免疫反应。我可以。 因此，活疫苗被广泛用于赋予免疫力，活疫苗有望占据很大的市场份额。

除了传统的疫苗生产方法外，各大公司还在使用病原体分子工程等先进技术生产活疫苗。 预计这一领域的发现将推动这一领域的增长。 例如，在 iScience 于 2021 年 7 月发表的一项研究中，100% 感染了基因缺失活减毒疫苗候选者（ORF022L）的鱼在传染性脾坏死病毒（ISKNV）攻击中存活下来，并且 ORF022L 显示出抗 ISKNV 特异性抗体. 诱导免疫相关基因的反应和上调。

未来几年，活疫苗领域有望占据较大份额。

预计在预测期内，亚太地区将占

亚太地区拥有印度和中国等主要水产养殖生产国，预计将占据水产养殖疫苗市场的很大份额，因为它拥有该地区最大的水产养殖业之一

根据联合国粮农组织（FAO）2022年报告，亚洲国家是主要生产国，占所有水生动物渔业和水产养殖产量的70%，在过去20年中，亚洲和非洲水产养殖产量翻了一番。 因此，作为最大的水产养殖生产区，该地区对水产养殖疫苗的需求很高，预计将推动研究市场的增长。

在亚太地区，根据联合国粮农组织2022年报告，中国约占世界渔业和水产养殖产量的35%，在全球水产养殖生产市场份额最高，有望成为主要市场. 此外，中国的水产养殖业正在扩张，这有望推动中国水产养殖疫苗市场的增长。 例如，2022年5月，中国将启用国新一号，这是世界上最大的浮式养鱼场之一，每年可生产3700吨鱼（长250米，宽45米，排水能力13万吨，15用于生产的大型坦克）。）推出。

因此，受上述因素影响，亚太地区在全球渔业和水产养殖产量中所占份额最高，水产养殖用疫苗需求量大，预计将占据很大的疫苗市场份额人类使用。

水产疫苗行业概况

水产养殖疫苗市场正在整合，一些主要参与者由于在水产养殖疫苗行业的重要参与，目前主导着市场。 水产养殖疫苗市场的主要参与者包括 Merck & Co., Inc.、Zoetis (PharmaQ)、Hipra、Technovax 和 Elanco。

其他福利：

• Excel 格式的市场预测 (ME) 表
• 3 个月的分析师支持

内容

第一章介绍

• 调查假设和市场定义
• 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

• 市场概览
• 市场驱动因素
  • 新兴国家的水产养殖业增加
  • 关于水产动物传染病多发及新产品开发
  • 由于抗生素耐药性而迅速引入疫苗
• 市场製约因素
  • 严格的疫苗生产法规
• 波特的五力分析
  • 新进入者的威胁
  • 买家/消费者的议价能力
  • 供应商的议价能力
  • 替代品的威胁
  • 竞争对手之间的竞争强度

第 5 章市场细分（按金额计算的市场规模 - 百万美元

• 按疫苗类型
  • 直播
  • 停用
  • 其他疫苗类型
• 按管理类型
  口服
  • 沉浸
  • 注射
• 地区
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 韩国
    • 其他亚太地区
  • 世界其他地方

第六章竞争格局

• 公司简介
  • Hipra
  • Merck & Co. Inc.
  • KBNP
  • Nisseiken Co., Ltd.
  • KoVax Ltd.
  • Kyoritsuseiyaku Corporation
  • Elanco
  • Vaxxinova International BV
  • Kyoto Biken Laboratories, Inc.

第7章 市场机会与今后动向

During the time frame of the forecast, the aquaculture vaccines market is expected to register a CAGR of 6.2%.

The COVID-19 pandemic had a significant impact on the animal industry, as due to the lockdown there was a significant impact on the logistics and supply chain of not only the essential pharmaceutical products for animals but also feed and other food items for animals, which affected the studied market. According to a Marine Policy research study published in September 2021, the COVID-19 pandemic affected the aquaculture industry in a variety of ways, including disruption in logistics and supply chains, which resulted in increased transportation costs (approximately 20-60% higher than usual), a decrease in market demand for fish, cancellation of orders from foreign buyers, an increase in input and maintenance costs, a labor shortage, and all these, COVID-19 had a significant impact on the aquaculture vaccine market. Also, with the consecutive second and third waves of COVID-19 infections in various countries, the market is set to observe sluggish growth in the short-term period. However, the market is expected to improve gradually and return to pre-pandemic growth levels in the forecast period due to an ease in lockdown restrictions.

The increasing consumption of aquatic animals is propelling the growth of the aquaculture industry, which is expected to be a primary growth factor for the market as aquaculture vaccines reduce the chance of infection and increase the yield of the product, which is expected to fuel growth in the aquaculture vaccines market over the forecast period. For instance, according to the 2022 report of the Food and Agriculture Organization (FAO) of the United Nations, the global production of aquatic animals stood at approximately 178 million tons, and of the total production, 63% (112 million tons) was harvested in marine waters (70% from capture fisheries and 30% from aquaculture) and 37% (66 million tons) in inland waters (83% from aquaculture and 17 percent from capture fisheries). Further, as per the same source, the global consumption of aquatic food is increasing, which is expected to further boost growth in aquaculture production. Consumption has increased from 9 kg in 1961 to 20.2 kg in recent decades, with the factors that have had the greatest impact on per capita consumption of aquatic foods being increasing supplies, shifting consumer preferences, technological developments, and rising incomes.Thus, the growing aquaculture industry is expected to drive the demand for aquaculture vaccines for a greater yield, which is expected to fuel growth in the aquaculture vaccines market over the forecast period.

Other factors that are expected to have a significant impact on the growth of the aquaculture vaccines market include the high prevalence of infectious diseases among aquatic animals and new product developments launched by the players in the market to tackle these diseases. For instance, according to a research study published in February 2022 by Frontiers, the anisakid nematodes were prevalent in fish across China, with a pooled incidence of 45.5%, and the incidence percentage for fresh fish was the greatest (58.1%). Fish from the East China Sea had the highest prevalence of anisakid nematodes (76.8%), while Eastern China had the highest prevalence rate (55.3%). Hence, due to the high prevalence of diseases, the demand for aquaculture vaccines is expected to grow, therefore propelling the market toward growth.

In addition to this, the launch of new aquaculture vaccines on the market is further expected to boost market growth. For instance, in April 2021, the Indian Council of Agriculture Research-Central Institute of Brackishwater Aquaculture (ICAR-CIBA) launched a recombinant vaccine called CIBA-Nodavac-R against viral nervous necrosis (VNN) that affects many marine, brackishwater, and freshwater fish, causing up to 100 percent mortality in larval and early juvenile stages. Similarly, in October 2021, a professor from Sylhet Agriculture University (SAU) in Bangladesh developed an oral vaccine for fish that can protect different species of fish from bacterial diseases and boost their production. The vaccine can be applied to the fish after mixing it with their feed.

Therefore, due to the above-mentioned factors, the aquaculture vaccines market is expected to grow over the forecast period. But strict regulations about vaccines are likely to slow the growth of the studied market over the next five years.

Aquaculture Vaccine Market Trends

Live Vaccine Type Segment is Expected to Hold a Significant Share in the Aquaculture Vaccines Market Over the Forecast Period

Live vaccinations include living, attenuated microbes that can still reproduce in the host (vaccinee). The microbes are "weak," which means they retain some immunogenic qualities while having lost much of their ability to cause disease. Live vaccinations often exhibit substantially higher immunogenicity than inactivated vaccines because they more closely mimic natural infection by activating a variety of immunologic responses, and in most cases, just one vaccination is enough to produce long-lasting, and occasionally even lifetime, immunity. Thus, the live vaccine type is widely used in administering immunity, due to which the live vaccine segment is expected to hold a significant share of the studied market.

In addition to the traditional ways of making vaccines, key players are also using advanced technologies, such as molecular manipulation of pathogens, to make live vaccines. Positive results from research studies in this area are expected to help the segment grow. For example, a research study published by iScience in July 2021 showed that 100% of the gene-deleted live attenuated candidate vaccine (ORF022L)-infected fish survived the infectious spleen and kidney necrosis virus (ISKNV) challenge, and ORF022L caused an anti-ISKNV specific antibody response and upregulation of immune-related genes.

Because of all of these things, the live vaccine segment is expected to have a large share of the market over the next few years.

Asia-Pacific Region is Expected to Occupy a Significant Share in the Aquaculture Vaccines Market Over the Forecast Period

The Asia-Pacific region is expected to hold a significant share of the aquaculture vaccines market due to the presence of one of the region's largest aquaculture industries, with major aquaculture-producing countries such as India and China.According to the 2022 report of the Food and Agriculture Organization (FAO) of the United Nations, Asian countries were the main producers, accounting for 70% of the total fisheries and aquaculture production of aquatic animals, and in the last 20 years, aquaculture production has doubled in Asia and Africa. Hence, due to being the largest aquaculture production region, the demand for aquaculture vaccines is expected to be high in the region, which is expected to boost growth in the studied market.

In the Asia-Pacific region, China is expected to be a major market owing to its highest share in the global aquaculture production market with about 35% of the global fisheries and aquaculture production, as per the 2022 report of the FAO of the United Nations. Furthermore, the aquaculture industry in China is expanding, which is expected to drive growth in the aquaculture vaccine market in the country. For instance, in May 2022, China launched one of the world's largest floating fish farms that can produce 3,700 tons of fish every year, called Guoxin 1, which is 250 meters (820 feet) long and 45 meters wide with a displacement of 130,000 tons and contains 15 huge tanks for production.

Therefore, due to the above-mentioned factors, the demand for aquaculture vaccines is expected to be high in the Asia-Pacific region due to the highest share in global fisheries and aquaculture production, and hence, the region is expected to hold a significant share in the aquaculture vaccines market over the forecast period.

Aquaculture Vaccine Industry Overview

The aquaculture vaccines market is consolidated, and a few of the major players are currently dominating the market due to their immense involvement in the aquaculture vaccines industry. Some of the key companies in the aquaculture vaccines market are Merck & Co., Inc., Zoetis (PharmaQ), Hipra, Technovax, and Elanco, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increase in Aquaculture Farming in Developing Countries
  • 4.2.2 High Prevalence of Infectious Diseases in Aquatic Animals and New Product Development
  • 4.2.3 Surge in Adoption of Vaccines due to Antibiotic Resistance
• 4.3 Market Restraints
  • 4.3.1 Stringent Manufacturing Regulations Associated with Vaccines
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million

• 5.1 By Vaccine Type
  • 5.1.1 Live
  • 5.1.2 Inactivated
  • 5.1.3 Other Vaccine Types
• 5.2 By Type of Administration
  • 5.2.1 Oral
  • 5.2.2 Immersion
  • 5.2.3 Injected
• 5.3 Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 Japan
    • 5.3.3.3 India
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Hipra
  • 6.1.2 Merck & Co. Inc.
  • 6.1.3 KBNP
  • 6.1.4 Nisseiken Co., Ltd.
  • 6.1.5 KoVax Ltd.
  • 6.1.6 Kyoritsuseiyaku Corporation
  • 6.1.7 Elanco
  • 6.1.8 Vaxxinova International BV
  • 6.1.9 Kyoto Biken Laboratories, Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS